ES2590128T3 - Procedimiento para la producción de sales de metanosulfonato de ralfinamida o sus enantiómeros R - Google Patents

Procedimiento para la producción de sales de metanosulfonato de ralfinamida o sus enantiómeros R Download PDF

Info

Publication number: ES2590128T3
Authority: ES; Spain
Prior art keywords: mixture; water; acetone; impurities; salt
Prior art date: 2010-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES11714958.3T

Other languages

English (en)

Spanish (es)

Inventor

Claudio Giordano

Erwin Waldvogel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Newron Pharmaceuticals SpA

Original Assignee

Newron Pharmaceuticals SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-27

Filing date

2011-04-06

Publication date

2016-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2590128(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-06 Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA

2016-11-18 Application granted granted Critical

2016-11-18 Publication of ES2590128T3 publication Critical patent/ES2590128T3/es

Status Active legal-status Critical Current

2031-04-06 Anticipated expiration legal-status Critical

Links

BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical class C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 title claims abstract description 34
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title claims abstract description 32
238000000034 method Methods 0.000 title claims abstract description 21
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
231100000024 genotoxic Toxicity 0.000 claims abstract description 20
230000001738 genotoxic effect Effects 0.000 claims abstract description 20
239000012535 impurity Substances 0.000 claims abstract description 20
150000003839 salts Chemical class 0.000 claims abstract description 20
239000000203 mixture Substances 0.000 claims abstract description 17
239000013557 residual solvent Substances 0.000 claims abstract description 15
239000002243 precursor Substances 0.000 claims abstract description 12
238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 11
239000002904 solvent Substances 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
238000002425 crystallisation Methods 0.000 claims abstract description 10
230000008025 crystallization Effects 0.000 claims abstract description 10
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims abstract description 10
239000007787 solid Substances 0.000 claims abstract description 10
229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims abstract description 7
-1 alkyl methanesulfonate Chemical compound 0.000 claims abstract description 6
238000000746 purification Methods 0.000 claims abstract description 6
150000002148 esters Chemical class 0.000 claims abstract description 5
230000008030 elimination Effects 0.000 claims abstract description 3
238000003379 elimination reaction Methods 0.000 claims abstract description 3
238000010438 heat treatment Methods 0.000 claims abstract description 3
239000002253 acid Substances 0.000 claims abstract 2
229910052799 carbon Inorganic materials 0.000 abstract description 5
230000015572 biosynthetic process Effects 0.000 description 9
239000013078 crystal Substances 0.000 description 9
238000005384 cross polarization magic-angle spinning Methods 0.000 description 8
239000000126 substance Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 4
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
SWWHCQCMVCPLEQ-UHFFFAOYSA-N propan-2-yl methanesulfonate Chemical compound CC(C)OS(C)(=O)=O SWWHCQCMVCPLEQ-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000022120 Jeavons syndrome Diseases 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
239000007888 film coating Substances 0.000 description 3
238000009501 film coating Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
CHQVNINIGBRKGZ-YDALLXLXSA-N (2s)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F CHQVNINIGBRKGZ-YDALLXLXSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
238000007596 consolidation process Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001144 powder X-ray diffraction data Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
101100456543 Caenorhabditis elegans mec-4 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 1
LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical group C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000005388 cross polarization Methods 0.000 description 1
238000001160 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
231100000583 toxicological profile Toxicity 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES11714958.3T 2010-04-27 2011-04-06 Procedimiento para la producción de sales de metanosulfonato de ralfinamida o sus enantiómeros R Active ES2590128T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10161207		2010-04-27
EP10161207		2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en)	2010-04-27	2011-04-06	Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Publications (1)

Publication Number	Publication Date
ES2590128T3 true ES2590128T3 (es)	2016-11-18

Family

ID=42634917

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES11714958.3T Active ES2590128T3 (es)	2010-04-27	2011-04-06	Procedimiento para la producción de sales de metanosulfonato de ralfinamida o sus enantiómeros R

Country Status (27)

Country	Link
US (2)	US9505708B2 (2)
EP (1)	EP2563355B1 (2)
JP (3)	JP5808392B2 (2)
KR (1)	KR101851118B1 (2)
CN (2)	CN102858330B (2)
AR (1)	AR085171A1 (2)
AU (1)	AU2011246707B2 (2)
BR (1)	BR112012027623B1 (2)
CA (1)	CA2794389C (2)
CY (1)	CY1117879T1 (2)
DK (1)	DK2563355T3 (2)
EA (1)	EA021389B1 (2)
ES (1)	ES2590128T3 (2)
HR (1)	HRP20161077T1 (2)
HU (1)	HUE030504T2 (2)
IL (1)	IL222532A (2)
LT (1)	LT2563355T (2)
ME (1)	ME02509B (2)
MX (1)	MX342697B (2)
NZ (2)	NZ700221A (2)
PL (1)	PL2563355T3 (2)
PT (1)	PT2563355T (2)
RS (1)	RS55084B1 (2)
SI (1)	SI2563355T1 (2)
SM (1)	SMT201600266B (2)
TW (1)	TWI492919B (2)
WO (1)	WO2011134763A1 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2563355T1 (sl) *	2010-04-27	2016-10-28	Newron Pharmaceuticals S.P.A.	Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
CN103804341B (zh) *	2012-11-13	2018-04-10	中国人民解放军军事医学科学院毒物药物研究所	酰胺衍生物及其医药用途
CN104761531B (zh) *	2014-01-03	2017-12-01	中国人民解放军军事医学科学院毒物药物研究所	镇痛活性化合物及其医药用途
CN104292128A (zh) *	2014-07-01	2015-01-21	南京正科制药有限公司	一种沙芬酰胺晶型a
CN115368310B (zh) *	2021-05-18	2025-06-27	奥库菲尔医药公司	合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
DK1423168T3 (da)	2001-09-03	2006-05-15	Newron Pharm Spa	Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
WO2004066987A2 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
DK1658062T3 (da)	2003-08-25	2010-05-31	Newron Pharm Spa	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1557166A1 (en)	2004-01-21	2005-07-27	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1870097A1 (en)	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) *	2006-06-19	2017-04-28	Newron Pharm Spa	High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
JP5315674B2 (ja) *	2007-11-19	2013-10-16	セントラル硝子株式会社	非水電池用電解液及びこれを用いた非水電池
US8530701B2 (en) *	2007-12-11	2013-09-10	Newron Pharmaceuticals, S.P.A.	High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en)	2007-12-19	2012-02-24	Newron Pharm Spa	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en)	2008-03-07	2009-09-11	Newron Pharmaceuticals S.P.A.	(s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
SI2563355T1 (sl) *	2010-04-27	2016-10-28	Newron Pharmaceuticals S.P.A.	Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov

2011
- 2011-04-06 SI SI201130927A patent/SI2563355T1/sl unknown
- 2011-04-06 ES ES11714958.3T patent/ES2590128T3/es active Active
- 2011-04-06 HR HRP20161077TT patent/HRP20161077T1/hr unknown
- 2011-04-06 LT LTEP11714958.3T patent/LT2563355T/lt unknown
- 2011-04-06 BR BR112012027623-9A patent/BR112012027623B1/pt active IP Right Grant
- 2011-04-06 EP EP11714958.3A patent/EP2563355B1/en active Active
- 2011-04-06 PT PT117149583T patent/PT2563355T/pt unknown
- 2011-04-06 NZ NZ700221A patent/NZ700221A/en unknown
- 2011-04-06 HU HUE11714958A patent/HUE030504T2/en unknown
- 2011-04-06 NZ NZ602648A patent/NZ602648A/en unknown
- 2011-04-06 CA CA2794389A patent/CA2794389C/en active Active
- 2011-04-06 RS RS20160665A patent/RS55084B1/sr unknown
- 2011-04-06 CN CN201180020748.2A patent/CN102858330B/zh active Active
- 2011-04-06 ME MEP-2016-169A patent/ME02509B/me unknown
- 2011-04-06 EA EA201291116A patent/EA021389B1/ru unknown
- 2011-04-06 AU AU2011246707A patent/AU2011246707B2/en active Active
- 2011-04-06 JP JP2013506566A patent/JP5808392B2/ja active Active
- 2011-04-06 DK DK11714958.3T patent/DK2563355T3/en active
- 2011-04-06 KR KR1020127030931A patent/KR101851118B1/ko active Active
- 2011-04-06 US US13/643,716 patent/US9505708B2/en active Active
- 2011-04-06 WO PCT/EP2011/055309 patent/WO2011134763A1/en not_active Ceased
- 2011-04-06 MX MX2012012093A patent/MX342697B/es active IP Right Grant
- 2011-04-06 PL PL11714958.3T patent/PL2563355T3/pl unknown
- 2011-04-06 CN CN201510387405.XA patent/CN105037188B/zh active Active
- 2011-04-18 TW TW100113339A patent/TWI492919B/zh active
- 2011-04-25 AR ARP110101401A patent/AR085171A1/es not_active Application Discontinuation
2012
- 2012-10-18 IL IL222532A patent/IL222532A/en active IP Right Grant
2015
- 2015-05-22 JP JP2015104930A patent/JP6345154B2/ja active Active
2016
- 2016-08-05 SM SM201600266T patent/SMT201600266B/it unknown
- 2016-08-10 CY CY20161100786T patent/CY1117879T1/el unknown
- 2016-10-12 US US15/291,202 patent/US9856207B2/en active Active
2017
- 2017-05-30 JP JP2017106571A patent/JP6450420B2/ja active Active

Also Published As

Publication number	Publication date
HUE030504T2 (en)	2017-05-29
CN105037188A (zh)	2015-11-11
LT2563355T (lt)	2016-09-26
JP6345154B2 (ja)	2018-06-20
AR085171A1 (es)	2013-09-18
JP6450420B2 (ja)	2019-01-09
BR112012027623B1 (pt)	2021-07-06
US20130039983A1 (en)	2013-02-14
EA201291116A1 (ru)	2013-04-30
SI2563355T1 (sl)	2016-10-28
WO2011134763A1 (en)	2011-11-03
CY1117879T1 (el)	2017-05-17
JP5808392B2 (ja)	2015-11-10
MX2012012093A (es)	2012-12-17
EP2563355A1 (en)	2013-03-06
NZ602648A (en)	2014-10-31
HK1179881A1 (en)	2013-10-11
NZ700221A (en)	2016-04-29
HRP20161077T1 (hr)	2016-10-21
KR20130094212A (ko)	2013-08-23
JP2013528577A (ja)	2013-07-11
IL222532A0 (en)	2012-12-31
RS55084B1 (sr)	2016-12-30
MX342697B (es)	2016-10-10
CN102858330B (zh)	2015-07-22
EA021389B1 (ru)	2015-06-30
US9856207B2 (en)	2018-01-02
SMT201600266B (it)	2016-08-31
TW201139344A (en)	2011-11-16
AU2011246707B2 (en)	2014-11-20
IL222532A (en)	2017-09-28
US9505708B2 (en)	2016-11-29
EP2563355B1 (en)	2016-06-08
HK1213872A1 (zh)	2016-07-15
CA2794389C (en)	2016-08-23
US20170029365A1 (en)	2017-02-02
CN102858330A (zh)	2013-01-02
ME02509B (me)	2017-02-20
JP2017197553A (ja)	2017-11-02
DK2563355T3 (en)	2016-09-12
CN105037188B (zh)	2017-06-23
JP2015180664A (ja)	2015-10-15
PT2563355T (pt)	2016-09-02
TWI492919B (zh)	2015-07-21
BR112012027623A2 (pt)	2016-08-09
CA2794389A1 (en)	2011-11-03
KR101851118B1 (ko)	2018-04-23
PL2563355T3 (pl)	2016-12-30

Publication	Publication Date	Title
JP7773987B2 (ja)	2025-11-20	スピロ環含有キナゾリン化合物
ES2590128T3 (es)	2016-11-18	Procedimiento para la producción de sales de metanosulfonato de ralfinamida o sus enantiómeros R
JP6211072B2 (ja)	2017-10-11	ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶
ES2968174T3 (es)	2024-05-08	Forma en estado sólido de succinato de ribociclib
WO2007136510A2 (en)	2007-11-29	Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
PT1371645E (pt)	2013-05-21	Utilização de (3s,2¿r)-glicopirrónio como produto farmacêutico
AU2014224456B2 (en)	2018-01-25	Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
JP6501773B2 (ja)	2019-04-17	結晶形態のダサチニブの塩
CA2510280C (en)	2011-09-27	Process for the preparation of the r,r (or s,s) configured glycopyrronium stereoisomer
KR102276281B1 (ko)	2021-07-13	의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
AU2006292328A1 (en)	2007-03-29	Novel crystal forms of irinotecan hydrochloride
ES2982660T3 (es)	2024-10-17	Forma cristalina B de compuesto de tetrahidrotienopiridina, método de preparación del mismo, composición y aplicación
ES2716420T3 (es)	2019-06-12	Clorhidrato de eliglustat cristalino
JP2019504046A (ja)	2019-02-14	チエノピリミジン化合物の結晶形
ES2645478T3 (es)	2017-12-05	Forma cristalina anhidra de Cabazitaxel, procedimiento de preparación y composiciones farmacéuticas de la misma
KR101548724B1 (ko)	2015-09-02	고체 형태의 항바이러스제 및 이의 제조방법
JP6827124B2 (ja)	2021-02-10	（１ｒ，３ｓ）−３−（５−シアノ−４−フェニル−１，３−チアゾール−２−イルカルバモイル）シクロペンタンカルボン酸のアミン塩
ES3061640T3 (en)	2026-04-06	Succinate of octahydrothienoquinoline compound, and crystals thereof
ES2778434T3 (es)	2020-08-10	Composiciones supersaturadas de compuestos de benzimidazol
CA2812227C (en)	2015-11-24	Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same
WO2022232060A1 (en)	2022-11-03	Processes for the synthesis of valbenazine
KR20210080235A (ko)	2021-06-30	초순수 트레프로스티닐의 효율적인 결정화 방법 및 그로부터 제조된 결정
CN104844577A (zh)	2015-08-19	埃索美拉唑镁的晶型
JP7045795B2 (ja)	2022-04-01	結晶性β－ラクタマーゼ阻害剤
CN113840605A (zh)	2021-12-24	N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途